立体定向放射外科治疗三叉神经痛中剂量与神经体积关系对疼痛复发的预测作用
本研究纳入2013至2015年接受伽玛刀手术的三叉神经痛患者58例共60条症状神经,评估三叉神经长度、体积、剂量-体积比及神经血管压迫对疼痛复发的影响。中位随访显示89.1%患者疼痛缓解,无多发性硬化患者1年及2年疼痛缓解维持概率分别为93%和84%。神经长度、体积及神经血管压迫不能预测复发,而小体积神经接受高剂量照射者复发更少。
要点
- 58例患者60条症状神经接受伽玛刀手术,其中15条继发于多发性硬化。
- 49例(89.1%)在伽玛刀术后中位1.9个月获得疼痛缓解(BNI I-IIIb级)。
- 小体积神经(<35%总体积)接受高剂量(≥80%等剂量线)者1年后复发更少。
核心结论
- 剂量与神经体积的比值可能预测伽玛刀术后三叉神经痛复发。
- 需要前瞻性研究确定最佳剂量与神经体积比值及其是否带来更长的无痛结局。
研究设计与样本
- 58例患者共60条症状神经于2013至2015年接受伽玛刀手术治疗三叉神经痛,其中15条症状神经继发于多发性硬化。
- 伽玛刀手术当天获取高分辨率MRI,评估神经血管压迫、三叉神经在后颅窝蛛网膜下腔内的长度和体积以及剂量与神经体积比值作为复发预测因素。
- 初次伽玛刀手术中位最大剂量为80 Gy,重复伽玛刀手术中位最大剂量为65 Gy。
主要发现
- 55例患者获得随访,49例(89.1%)在伽玛刀术后中位1.9个月报告疼痛缓解(BNI I-IIIb级)。
- 无多发性硬化患者维持疼痛缓解(BNI I-IIIb级)且无需恢复或增加药物的概率1年为93%、2年为84%;全部患者1年为68%、2年为51%。
- 神经长度、神经体积、靶点距脑干距离及神经血管压迫的存在均不能预测疼痛复发。
- 接受高剂量(≥80%等剂量线)的小体积神经(<35%总体积)患者1年后三叉神经痛复发可能性更低(平均复发时间:<35%组32.2±4.0个月 vs >35%组17.9±2.8个月,log-rank检验,χ2=4.3,p=0.039)。
局限性
- 需要前瞻性研究确定最佳剂量与神经体积比值及其是否带来更长的无痛结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE Approximately 75%-92% of patients with trigeminal neuralgia (TN) achieve pain relief after Gamma Knife surgery (GKS), although a proportion of these patients will experience recurrence of their pain. To evaluate the reasons for durability or recurrence, this study determined the impact of trigeminal nerve length and volume, the nerve dose-volume relationship, and the presence of neurovascular compression (NVC) on pain outcomes after GKS for TN. METHODS Fifty-eight patients with 60 symptomatic nerves underwent GKS for TN between 2013 and 2015, including 15 symptomatic nerves secondary to multiple sclerosis (MS). High-resolution MRI was acquired the day of GKS. The median maximum dose was 80 Gy for initial GKS and 65 Gy for repeat GKS. NVC, length and volume of the trigeminal nerve within the subarachnoid space of the posterior fossa, and the ratio of dose to nerve volume were assessed as predictors of recurrence. RESULTS Follow-up was available on 55 patients. Forty-nine patients (89.1%) reported pain relief (Barrow Neurological Institute [BNI] Grades I-IIIb) after GKS at a median duration of 1.9 months. The probability of maintaining pain relief (BNI Grades I-IIIb) without requiring resumption or an increase in medication was 93% at 1 year and 84% at 2 years for patients without MS, and 68% at 1 year and 51% at 2 years for all patients. The nerve length, nerve volume, target distance from the brainstem, and presence of NVC were not predictive of pain recurrence. Patients with a smaller volume of nerve (< 35% of the total nerve volume) that received a high dose (≥ 80% isodose) were less likely to experience recurrence of their TN pain after 1 year (mean time to recurrence: < 35%, 32.2 ± 4.0 months; > 35%, 17.9 ± 2.8 months, log-rank test, χ2 = 4.3, p = 0.039). CONCLUSIONS The ratio of dose to nerve volume may predict recurrence of TN pain after GKS. Prospective studies are needed to determine the optimal dose to nerve volume ratio and whether this will result in longer pain-free outcomes.
引用
- Wolf A, Tyburczy A, Ye JC, et al. The relationship of dose to nerve volume in predicting pain recurrence after stereotactic radiosurgery in trigeminal neuralgia. J Neurosurg. 2017. PMID: 28524797. doi:10.3171/2016.12.JNS161862
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。